Talee Bio

Our mission at Talee Bio is to change the course of cystic fibrosis and other genetic lung diseases by developing novel genetic treatments.  Our gene therapy technologies are designed to overcome the barriers that have so far prevented effective genetic treatments for cystic fibrosis.

Talee Bio has two gene therapy product candidates to treat cystic fibrosis. The major hurdles of gene therapy for cystic fibrosis are poor efficacy (i.e., transduction efficiency, expression persistence, packaging capacity, avoidance of immunogenicity), low safety and tolerability (including genotoxicity for those vectors that result in genomic integration), and inability to manufacture sufficient vector.  Our proprietary platform technologies and our product candidates are designed to address all of these deficiencies.

Talee Bio’s academic founders and collaborators at the University of Iowa and Children’s Hospital of Philadelphia have more than 100 years of collective experience in cystic fibrosis biology, pathophysiology, and gene therapy.